Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

EMA Knocks Back Pfizer’s Xeljanz For Rheumatoid Arthritis and Otsuka’s Delamanid For TB

This article was originally published in The Pink Sheet Daily

Executive Summary

The EMA has rejected Pfizer’s tofacitinib for the second time on safety grounds and Otsuka’s delamanid due to a short trial length.

You may also be interested in...



Pfizer's Xeljanz Set To Lag Lilly's Olumiant In Europe Following Past Rebuffs

Pfizer's Xeljanz (tofacitinib) has finally won a green light from the European Medicines Agency's CHMP for treating rheumatoid arthritis, but its two previous rejections by the panel on safety grounds might curb sales.

India’s Drug Advisory Body Calls For Larger Study To Approve Pfizer’s Xeljanz

The New Drug Advisory Committee said the number of patients enrolled in Pfizer’s Xeljanz trials was not statistically significant to recommend marketing authorization.

EMA Birth Control Safety Review Shows PRAC’s Clout, Concern About Newer Products

The Pharmacovigilance Risk Assessment Committee is assessing whether use of third- and fourth-generation combined oral contraceptives should be limited to women who cannot take other birth control pills; this is the ninth group of drugs PRAC has been asked to review.

Topics

Related Companies

UsernamePublicRestriction

Register

SC143384

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel